Application of SLC26A2 gene as broiler tibial cartilage dysplasia marker

By detecting the differences in gene or protein expression of SLC26A2, the diagnosis and treatment problems of tibial cartilage dysplasia in broiler are solved, and new diagnosis and treatment methods for TD are provided, which improves the level of poultry health management and reduces economic losses.

CN119040454AActive Publication Date: 2024-11-29SOUTH CHINA AGRICULTURAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411363054.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-29
Estimated Expiration
2044-09-27

AI Technical Summary

Technical Problem

Tibial dyschondroplasia (TD) in broiler chickens has problems of difficulty in diagnosis, high cost and serious economic losses in poultry farming. The existing diagnostic methods are complex and not cost-effective, and there is a lack of effective genotype diagnosis methods.

Method used

Diagnosing and predicting tibial cartilage dysplasia in broiler by detecting differences in SLC26A2 gene or protein expression, using real-time quantitative PCR and specific antibodies to recognize SLC26A2 gene or protein, providing diagnostic tools and therapeutic drugs to activate SLC26A2 gene or protein to treat TD.

Benefits of technology

Early diagnosis and prognostic evaluation of tibial cartilage dysplasia in broiler chickens is achieved, and a new treatment strategy for TD is provided, which reduces economic losses in breeding and improves the level of poultry health management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040454A_ABST
    Figure CN119040454A_ABST
Patent Text Reader

Abstract

The invention discloses application of an SLC26A2 gene as a broiler tibial cartilage dysplasia marker, belongs to the technical field of molecular biology, and comprises application of a product for detecting SLC26A2 in preparation of a broiler tibial cartilage dysplasia diagnosis tool and application of an activator of SLC26A2 in preparation of a broiler tibial cartilage dysplasia treatment medicine. Experiments in the embodiment of the invention prove that the expression of the SLC26A2 gene in normal tissues and TD tissues of the broiler chicken is obviously different, and the SLC26A2 gene can be used as a novel diagnosis and prognosis biomarker for the broiler chicken tibial cartilage dysplasia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biology, and particularly relates to application of SLC26A2 gene as a marker for tibial chondrodysplasia in broilers. Background Art

[0002] Tibial dyschondroplasia (TD) in broilers is a metabolic bone disease caused by metabolic disorders during the rapid growth period of poultry. This condition not only impairs the production performance of poultry, but also causes significant economic losses to the poultry farming industry. The main characteristics of TD include cartilage degeneration in the tibia, increased thickness of the growth plate, obstructed vascular supply, and the formation of opaque cartilage plugs. As the farming model shifts from traditional free-range farming to more intensive intensive farming, the incidence of TD has increased. In my country, the incidence of TD has exceeded 10% and accounts for approximately 30% of all poultry bone diseases, which poses a challenge to my country's growing poultry farming industry. Therefore, the occurrence mechanism of TD and its preventive measures are gradually becoming the focus of research.

[0003] At present, the diagnosis of tibial dyschondroplasia (TD) in broilers mainly relies on the observation of morphological changes in the tibial growth plate, although imaging diagnostic tools such as X-ray examinations can also be used as auxiliary means to evaluate the condition of TD. However, these traditional diagnostic methods are not cost-effective in actual poultry farming operations, especially in large-scale intensive farms or free-range environments of individual farmers, they are complicated and time-consuming. In addition, in clinical observations, most broiler TD symptoms are subclinical. When broilers show obvious lameness symptoms, it is the late stage of the disease. The disease is generally more serious and often causes irreversible damage to broilers. Studies have begun to explore new diagnostic approaches. Publication No. CN114088855 A discloses a fecal biomarker for early diagnosis of tibial dyschondroplasia in broilers and its application. The application proposes an early diagnosis method based on metabolomics analysis of fecal samples, which aims to achieve early detection of TD by screening specific biomarkers. Therefore, developing an efficient clinical diagnostic method for broiler TD and corresponding targeted drugs will have important clinical value and socioeconomic benefits for improving poultry health management, reducing economic losses, and promoting the sustainable development of the poultry industry. Summary of the invention

[0004] One of the purposes of the present invention is to provide a method for diagnosing tibial dyschondroplasia in broiler chickens by detecting the difference in expression of SLC26A2 gene or protein.

[0005] A second object of the present invention is to provide a method for predicting the prognosis of tibial chondrodysplasia by detecting the difference in expression of SLC26A2 gene or protein.

[0006] A third object of the present invention is to provide a method for treating tibial chondrodysplasia in broiler chickens by activating the SLC26A2 gene or the SLC26A2 protein.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] The present invention provides an application of the SLC26A2 gene as a marker for tibial dyschondroplasia in broilers, including an application of a product for detecting SLC26A2 in the preparation of a diagnostic tool for tibial dyschondroplasia in broilers.

[0009] Furthermore, the product for detecting SLC26A2 includes a product for detecting the expression level of the SLC26A2 gene.

[0010] Furthermore, the product for detecting the expression level of the SLC26A2 gene includes a product capable of quantifying the mRNA of the SLC26A2 gene, or a product capable of quantifying the SLC26A2 protein.

[0011] Furthermore, the reagent capable of quantifying SLC26A2 gene mRNA includes primers used in real-time quantitative PCR to specifically amplify SLC26A2 gene, and the primer sequences are shown in SEQ ID NO.6 and SEQ ID NO.7; the reagent capable of quantifying SLC26A2 protein includes an antibody that specifically binds to SLC26A2 protein.

[0012] There is no particular limitation on the number of amino acids recognized by the anti-SLC26A2 antibody or other fragments used in the detection products and diagnostic tools based on the SLC26A2 gene provided by the present invention, as long as the antibody can bind to SLC26A2.

[0013] The present invention provides a method for diagnosing tibial chondrodysplasia in broiler chickens, the method being as follows:

[0014] (1) obtaining broiler chicken samples;

[0015] (2) Detecting the SLC26A2 gene or protein expression level in broiler chicken samples;

[0016] (3) correlating the detected SLC26A2 gene or protein expression level with whether the broiler chicken to be tested is diseased;

[0017] (4) If the expression level of the detected SLC26A2 gene or protein is reduced, it indicates that the broiler is diagnosed with tibial chondrodysplasia, or the broiler is determined to have a poor prognosis.

[0018] The present invention also provides the use of an activator of SLC26A2 in preparing a medicine for treating tibial chondrodysplasia in broilers.

[0019] Furthermore, the activator can promote or enhance the expression or activity of SLC26A2 or a substance involved in an upstream or downstream pathway of SLC26A2.

[0020] Furthermore, the activator of the SLC26A2 gene or SLC26A2 protein mentioned above is not limited, as long as it can promote or enhance the expression activity of SLC26A2 or substances involved in the upstream or downstream pathways of SLC26A2, and is effective for treating tibial chondrodysplasia in broilers.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention discloses the application of SLC26A2 gene as a marker of tibial chondrodysplasia in broilers. By detecting the content of SLC26A2 gene in broilers, it is determined whether the broilers are at high risk of TD. This discovery is of great significance for the clinical diagnosis and prevention strategy formulation of TD, especially in the absence of a diagnostic method for TD genotype in broilers. This progress is particularly critical. In addition, the application of SLC26A2 gene in the diagnosis, treatment and prognosis evaluation of TD in broilers provides a new direction for the differentially expressed genes of TD in broilers as biomarkers for clinical diagnosis, and may also become a target for the development of new treatment strategies, promote the development of TD prevention and control technology in broilers, improve the health of broilers and improve breeding efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a diagram of gene and protein expression levels after silencing of SLC26A2 in chondrocytes in an embodiment of the present invention; wherein: Figure 1 (A) is the gene expression level diagram after silencing of SLC26A2 gene in chondrocytes. Figure 1 (B) is the protein expression level diagram after silencing of SLC26A2 in chondrocytes. Figure 1 (C) is the band diagram of SLC26A2 and GAPDH internal reference proteins.

[0024] Figure 2 This is a diagram of gene and protein expression levels after overexpression of the SLC26A2 gene in chondrocytes in an embodiment of the present invention; wherein, Figure 2 (A) is the gene expression level diagram after overexpression of SLC26A2 gene in chondrocytes. Figure 2 (B) is the band diagram of SLC26A2 and GAPDH internal reference proteins. Figure 2 (C) is a graph showing protein expression levels after overexpression of the SLC26A2 gene in chondrocytes.

[0025] Figure 3 This is a graph showing the expression level of the SLC26A2 gene in chondrocytes in an embodiment of the present invention; wherein: Figure 3 (A) is the expression level of SLC26A2 gene after chondrocytes were challenged with 10 μM concentration of Thiram. Figure 3 (B) is a graph showing the expression level of SLC26A2 gene in TD tissue of broiler chickens; Figure 3 (C) is a graph showing the expression levels of genes related to chondrocyte development after silencing of SLC26A2 in chondrocytes.

[0026] Figure 4 This is a graph showing the expression levels of genes related to chondrocyte development after the chondrocyte SLC26A2 gene is overexpressed in an embodiment of the present invention.

[0027] Figure 5 This is a graph showing the protein expression level of SLC26A2 in broiler TD tibia tissue and chondrocytes challenged with Thiram in an example of the present invention.

[0028] Figure 6 This is a graph showing the expression levels of proteins related to chondrocyte development after silencing of chondrocyte SLC26A2 in an embodiment of the present invention.

[0029] Figure 7 This is a graph showing the expression levels of proteins related to chondrocyte development after overexpression of chondrocyte SLC26A2 in an embodiment of the present invention. DETAILED DESCRIPTION

[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0032] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0033] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments:

[0034] Example

[0035] 1. Sample acquisition

[0036] Twenty healthy AA broilers of similar weight at one day of age were purchased from the Shandong Breeding Cooperative, and were adaptively raised until 3 days of age. They were then randomly divided into two groups, 10 in each group, the control group CON group and the TD group (thiram group). The CON group was fed a conventional basal diet, and the TD group was fed a diet with 50 mg / kg of thiram from 4 to 21 days of age. Tibia samples of broilers were collected at 21 days of age and quickly frozen in liquid nitrogen for subsequent fluorescence quantitative PCR and WB experiments.

[0037] 2. Obtaining primary cells from broiler chickens and TD chondrocyte model induced by thiram

[0038] Select 15-day-old chicken embryos and place them on a clean bench after alcohol disinfection. Use the root of forceps to knock open the chicken embryo air chamber. Use eye forceps to cut the membrane to extract the tissue and place them in a sterile culture dish. Then use eye scissors to remove the tibia along the root of the chicken embryo thigh and wash it three times with PBS. Use cell forceps to separate the articular cartilage. In a sterile culture dish containing PBS, cut the cartilage into small pieces of 1-3 mm with ophthalmic scissors, then transfer it to a new centrifuge tube and wash it twice with PBS. After that, digest the tissue with 0.2% collagenase IV (Cat. No.: 2091mg100, Biofroxx, Germany) at 37°C for 12 hours. Subsequently, the tissue digestion solution was placed in a 400-mesh filter, the isolated primary chondrocytes were collected, and the cells were washed twice with PBS. Finally, chondrocytes were diluted with DMEM / F12 medium (Cat. No. C11330500BT, Gibco, USA) supplemented with 15% fetal bovine serum (FBS, Yilang, China) and 1% penicillin-streptomycin (Cat. No. G4003, Servicebio, Wuhan) to a seeding density of 5 × 10 5 The cells / mL culture plate was placed in a constant temperature incubator at 5% CO2 and 37°C. The chondrocytes were challenged with 10 μM thiram culture medium to detect changes in gene levels for 24 hours and changes in protein levels for 48 hours.

[0039] 3. Chondrocyte transfection

[0040] When the density of chondrocytes reached 70-80%, they were washed three times with PBS. The transfection reagent and siRNA or pEGFP-SLC26A2 plasmid DNA were diluted with opti-MEM (Cat. No.: 31985-070, Gibco, USA) and DMEM / F12 medium (Cat. No.: C11330500BT, Gibco, USA) containing 10% FBS (Yilang, China) but without double antibody, and transfection was performed according to the instructions of Lipofectamine3000 (Cat. No.: L3000008, Thermo, USA). siRNA was synthesized by GenePharma (GenePharma, China). After transfection, the culture plate was placed in an incubator for further culture. After 24-72 hours of culture, the cells were collected to detect the transfection efficiency. The si-SLC26A2 RNA oligo sequence is shown in Table 1 (according to the WIPOST.26 standard, the sequence in the sequence list changes all "U" (representing uracil in the nucleotide sequence) to "T").

[0041] Table 1

[0042]

[0043] ① Primer design: According to the CDS region of the SLC26A2 gene sequence found on NCBI, a suitable primer was designed at each end to completely amplify the CDS region of SLC26A2. After the primer specificity was tested by Blast, it was handed over to Qingke Biotechnology Co., Ltd. for synthesis. Then the sequences of the vector pEGFP-N1 and SLC26A2 were compared, and the appropriate restriction sites were selected. The restriction sites and protective bases were added to the designed primers. After the primer specificity was tested by Blast, it was handed over to Qingke Biotechnology Co., Ltd. for synthesis. The sequences of the two pairs of primers used are shown in Table 2 ((According to the requirements of the WIPOST.26 standard, the sequences in the table in the sequence list will change all "U" (representing uracil in the nucleotide sequence) to 'T'")).

[0044] Table 2

[0045]

[0046] ②cDNA synthesis: According to the experimental method in point 4, the total RNA in the tibia cartilage tissue of broiler chickens was extracted, and the concentration was measured by a micro-spectrophotometer and quantified to 500 ng / μL. Then, according to the instructions of the reverse transcription kit, the following system was prepared, as shown in Table 3, Table 4 and Table 5.

[0047] Table 3 Reverse transcription first step system

[0048] Components Volume (μL) <![CDATA[RNase-free ddH2O]]> 6 Total RNA 2

[0049] Heat at 65°C for 5 min, quickly cool on ice, and keep on ice for 2 min.

[0050] Table 4 Reverse transcription second step system

[0051] Components Volume (μL) The mixture from the previous step 8 5×gDNA wiper Mix 2

[0052] Mix by gently pipetting and incubate at 42°C for 2 min.

[0053] Table 5 Reverse transcription third step system

[0054] Components Volume (μL) The mixture from the previous step 10 10×RT Mix 2 HiScript III Enzyme Mix 2 Oligo(dT)20VN 1 <![CDATA[RNase-free ddH2O]]> 5

[0055] After mixing by pipetting, the mixture was placed in a PCR instrument and reacted at 25°C for 5 min, 37°C for 45 min, and 85°C for 5 s. The product was stored in a -80°C refrigerator.

[0056] ③ Product amplification: Dilute the cDNA product obtained in the previous step 10 times. Prepare the following reaction system according to the Taq enzyme instruction manual, as shown in Table 6.

[0057] Table 6 PCR reaction system

[0058] Components Volume (μL) Template DNA 2 Upstream primer (10 μM) 2.5 Downstream primer (10 μM) 2.5 2×Magic Green Taq SuperMix 25 <![CDATA[ddH2O]]> 18

[0059] The reaction procedure is shown in Table 7.

[0060] Table 7 PCR reaction program

[0061]

[0062] ④ Product recovery: gel preparation, add the amplified product obtained in the previous step and DNA Maker to the wells respectively. Perform electrophoresis at 110V for 30min. After the electrophoresis, perform gel imaging in a multifunctional imager. A bright band slightly larger than 1000bp is observed, and the product fragment is completely cut out.

[0063] ⑤ Product purification: Recover DNA according to the steps in the gel recovery and purification kit instructions and measure the concentration.

[0064] ⑥ Secondary amplification: The gel-recovered product is used as template DNA, and primers with restriction sites and homology arms are added to amplify again according to the reaction system and procedures of step ③, and gel recovery is performed. The gel-recovered product is sequenced by Sangon Biotechnology Co., Ltd.

[0065] ⑦ Enzyme digestion: pEGFP-N1 vector strain was spread on an agar plate and placed in a 37°C incubator overnight. On the second day, a single colony was picked and placed in 10 mL of broth medium, and cultured at 37°C for 12 hours. Then, the plasmid was extracted according to the instructions of the plasmid extraction kit, and the concentration was measured and quantified to 500 ng / μL. The vector plasmid was digested with a fast-cutting enzyme, and the system is shown in Table 8.

[0066] Table 8

[0067] Components Volume (μL) QuickCut green Buffer 5 Empty plasmid 2 Hind III fast digestion enzyme 1 XheⅠ fast digestion enzyme 1 <![CDATA[ddH2O]]> 41

[0068] The reaction was carried out at 37°C for 5 hours. The reaction product was subjected to nucleic acid electrophoresis, and then recovered using a kit to obtain a purified linearized vector and measure its concentration.

[0069] ⑧Homologous recombination: The DNA fragment and the linearized vector were subjected to recombination reaction according to the ratio specified in the instruction manual. The recombination reaction system is shown in Table 9.

[0070] Table 9

[0071] Components Volume (μL) DNA fragments (20ng / μL) 3 Linearized vector (20ng / μL) 1 2×Sealess Master Mix 5 <![CDATA[ddH2O]]> 1

[0072] The mixture was reacted at 50°C for 30 min, and then the centrifuge tube was placed on ice.

[0073] ⑨Transformation: Take 5μL of the ligation solution to 50μL of the thawed DH5α competent cells, mix gently, place on ice for 30 minutes, heat shock in a 42℃ water bath for 30 seconds, immediately place on ice for 2 minutes, add 500μL of broth medium (without antibiotics), shake and culture at 37℃ for 60 minutes. Then centrifuge at 3000g for 2 minutes, discard part of the supernatant, and gently blow with a pipette to mix the bacteria thoroughly. Pipette 200μL of the bacterial solution to plate and place in a 37℃ constant temperature incubator overnight.

[0074] ⑩ Identification: After the colonies grow, pick a single colony and culture it in 500μL broth medium with shaking for 3 hours. Then use the bacterial liquid as a template for DNA amplification and perform nucleic acid electrophoresis on the amplified product. After confirming the positive colony, add the remaining culture medium into 10mL broth medium and culture it at 37℃ with shaking for 14-16 hours.

[0075] Plasmid extraction: The overexpression plasmid was extracted according to the instructions of the plasmid extraction kit. After collection, the concentration was measured and quantified to 500 ng / μL. The SLC26A2 overexpression plasmid transfection system is shown in Table 10.

[0076] Table 10

[0077]

[0078] Experimental results:

[0079] like Figure 1 As shown in the figure: after si-SLC26A2 was transfected into broiler tibial chondrocytes, the corresponding gene and protein expressions decreased, indicating that the si-SLC26A2 transfected broiler tibial chondrocyte model was successfully established; Figure 2 As shown: By constructing a pEGFP-SLC26A2 overexpression vector and transfecting it into broiler tibial chondrocytes, the SLC26A2 gene expression increased significantly after 24 hours, and the protein also increased significantly after 48 hours. This shows that the SLC26A2 overexpression vector was successfully constructed. Through the above experiments, it can be seen that after the corresponding treatment, the corresponding gene and protein expression levels of SLC26A2 changed significantly, indicating that the SLC26A2 interference and overexpression model was successfully constructed.

[0080] 4. Total RNA extraction and real-time fluorescence quantitative PCR reaction (qRT-PCR) of tibial growth plate tissue and cells

[0081] When the cells were about 80% full of culture dishes, 10 μM of thiram was used to attack the cells to construct a TD in vitro cell model, and then the total RNA of the tibial growth plate and cells was extracted using a total RNA extraction kit (FastPure Cell / Tissue Total RNA Isolation Kit V2, Vazyme, China, Catalog No.: RC112-01). The gDNA of the total RNA was removed, and the mRNA was reversely transcribed into cDNA using a reverse transcription kit (HiScript IIQ RT SuperMix for qPCR (+gDNA wiper), Vazyme, China, Catalog No. R223-01) according to the specifications of the kit. RT-qPCR was performed using the universal SYBR Green Fast qPCRMix (ABclonal, China, Catalog No. RK21203). In the RT-qPCR instrument (qTOWER3; analytikjena, Germany), the program was set according to the qPCR Mix specification. The primer sequences for RT-qPCR were designed using the primer design tool (National Center for Biotechnology Information, USA), and the primers were synthesized by China Qingke Company. -△△CT Methods The target gene expression level was normalized to GAPDH, and the primer sequences were shown in Table 11 ((according to the WIPOST.26 standard, all "U" (representing uracil in the nucleotide sequence) in the sequence listing was changed to 'T'")).

[0082]

[0083] Experimental results:

[0084] Figure 3The expression level of SLC26A2 gene in chondrocytes is shown in Figure 2. Figure 3 As can be seen in (A), after chondrocytes were challenged with 10 μM concentration of Thiram, the expression of SLC26A2 gene decreased significantly; Figure 3 As can be seen from (B), in the TD tissue of broiler chickens, the expression level of the SLC26A2 gene in the tibial cartilage tissue of the TD group broiler chickens was significantly lower than that of the CON gene in the control group; thus, it can be seen that the results of the in vivo and in vitro experiments in broiler chickens are consistent, indicating that when broiler chickens develop TD, the expression level of their SLC26A2 gene is significantly reduced, indicating that SLC26A2 can be used as an important detection indicator for TD in broiler chickens. Figure 3 As can be seen in (C), after si-SLC26A2 was transfected into chondrocytes, the cartilage development-related genes Runx2 and ALP were significantly downregulated, while the MMP13 gene was significantly increased, indicating that interfering with the expression of the SLC26A2 gene significantly affected the differentiation and development of chondrocytes.

[0085] Figure 4 This is a graph of the expression levels of genes related to chondrocyte development after overexpression of SLC26A2 in chondrocytes. The pEGFP-SLC26A2 plasmid was transfected into chondrocytes, and its gene expression level was detected by qRT-PCR. It can be seen from the figure that after overexpression of pEGFP-SLC26A2, the expression levels of cartilage development-related genes Runx2 and ALP were significantly increased, while the MMP13 gene was significantly downregulated; this indicates that overexpression of the SLC26A2 gene contributes to chondrocyte differentiation.

[0086] The above experiments show that the SLC26A2 gene is an important cartilage development-related gene. At the same time, after broiler chickens develop TD, detecting the expression of the SLC26A2 gene can help determine whether the broiler chickens have a high risk of developing TD.

[0087] 5. Tibial growth plate tissue and cell protein extraction and protein immunoblotting (Western Blotting)

[0088] Tissue samples were homogenized on ice using RIPA lysis buffer (Beyotime, China, Cat. No. P0013B) supplemented with 1% PMSF protease inhibitor (Beyotime, China, Cat. No. ST505). The protein concentration was quantified to 1 μg / μL using a BCA protein detection kit (NCM, China, Cat. No. WB6501), and then the sample was mixed with SDS-PAGE loading buffer (NCM, China, Cat. No. P0015) and heated at 100°C for 10 minutes to denature the protein and expose the binding site of the primary antibody; PAGE gel was prepared using a one-step PAGE gel rapid preparation kit (12%) (Vazyme, China, Cat. No. E304-01). A 10 μL aliquot of the lysate mixture was loaded onto an SDS-PAGE gel and electrophoresed at 80 V for 2 hours; the proteins on the PAGE gel were transferred to a polyvinylidene fluoride (PVDF) membrane with a pore size of 0.45 μm ( PVDF membrane (Membranes, Millipore, USA, catalog no. IPVH00010) was transferred using the wet transfer method at 150 mA for 2 hours, and the instrument was cooled to 0-4°C during the process; nonspecific antigens on PVDF were blocked by incubating the membrane with 5% skim milk powder (Servicebio, China, catalog no. GC310001) dissolved in TBS (Tris-buffered saline) with 0.1% Tween-20 on a horizontal oscillator at room temperature for 1.5 hours, and then the membrane was incubated with the primary antibody at 4°C for 16 hours, and then incubated with the secondary antibody labeled with horseradish peroxidase (HRP) for 1 hour at room temperature. The blots were developed using the NcmECL ultra-enhanced chemiluminescence (ECL) kit (NCM, China, Cat. No. P10100), the chemiluminescent signals of the blots were captured using UVP ChemStudio (Analytik Jena, Germany), and the grayscale value of each blot was analyzed using ImageJ software (National Institutes of Health, USA) and normalized using GAPDH.

[0089] Experimental results:

[0090] Figure 5 Figure 2 is the protein expression level of SLC26A2 in broiler TD tibia tissue and chondrocytes after thiram infection. Broiler tibia chondrocytes were infected with 10 μM thiram and the protein expression level of SLC26A2 was detected 48 hours later. Figure 5 (B) shows that the expression of SLC26A2 protein was significantly downregulated after thiram poisoning chondrocytes. Figure 5As can be seen from (A), in the tibial cartilage tissue of TD broiler chickens, the SLC26A2 protein in the TD group was also significantly downregulated compared with the control group CON; this shows that the protein expression in the in vivo and in vitro experiments showed consistency, indicating that SLC26A2 was significantly downregulated when broiler chickens developed TD, and based on the above Figure 3 The experimental results show that the expression levels of SLC26A2 gene and protein are consistent in TD broiler tibial cartilage tissue and cells.

[0091] Figure 6 Figure 2 is the expression level of chondrocyte development-related proteins after silencing of SLC26A2 in chondrocytes. After si-SLC26A2 was transfected into chondrocytes for 48 hours, the expression level of chondrocyte development-related proteins was detected by WB experiment. Figure 6 As shown in the figure, it can be seen that compared with the NC group, the expression levels of cartilage development-related proteins COL2α1, BMP2, Runx2, ACAN and ALP in the SLC26A2 gene interference group were significantly downregulated, indicating that the expression of SLC26A2 protein was interfered with and the development of chondrocytes was hindered.

[0092] Figure 7 Figure 2 is the expression level of chondrocyte development-related proteins after overexpression of SLC26A2 in chondrocytes. The expression level of cartilage development-related proteins was detected 48 hours after pEGFP-SLC26A2 was transfected into chondrocytes. The detection results are shown in Figure 7 As shown in the figure, it can be seen that the protein expression levels of cartilage development-related proteins ACAN, BMP2, COL2α1, SOX9 and Runx2 were significantly upregulated compared with the empty group (pEGFP group), which indicates that overexpression of the SLC26A2 gene contributes to the development of chondrocytes.

[0093] In summary, the SLC26A2 gene was significantly downregulated in the tibial cartilage tissue and cells of TD broiler chickens, and the expression levels of its gene and protein remained consistent. The consistency of in vivo and in vitro experiments shows that SLC26A2 is an important indicator gene for TD in broiler chickens; at the same time, after interfering with and overexpressing the SLC26A2 gene in tibial chondrocytes of broiler chickens using fluorescent quantitative PCR and WB experiments, the expression levels of cartilage development-related genes and proteins were also consistent. The above experimental results in this embodiment show that the SLC26A2 gene can be used as a detection indicator to determine whether TD occurs in broiler chickens.

[0094] The above is a detailed introduction to the application of the SLC26A2 gene disclosed in the present invention as a marker for tibial chondrodysplasia in broilers. Specific examples are used herein to illustrate the principles and implementation methods of the present invention, and the description of the above embodiments is only used to help understand the method of the present invention and its core idea. It should be pointed out that for ordinary technicians in this technical field, without departing from the principles of the present invention, the present invention can also be improved and modified in a number of ways, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.

Claims

1. The use of SLC26A2 gene as a marker for tibial chondrodysplasia in broilers is characterized in that: Includes the use of products for detecting SLC26A2 in the preparation of diagnostic tools for tibial chondrodysplasia in broiler chickens.

2. The use according to claim 1, characterized in that: The product for detecting SLC26A2 includes a product for detecting the expression level of the SLC26A2 gene.

3. The use according to claim 2, characterized in that: The product for detecting the expression level of the SLC26A2 gene includes a product capable of quantifying the mRNA of the SLC26A2 gene, or a product capable of quantifying the SLC26A2 protein.

4. The use according to claim 3, characterized in that: The reagent capable of quantifying SLC26A2 gene mRNA includes primers used in real-time quantitative PCR to specifically amplify SLC26A2 gene, and the primer sequences are shown in SEQ ID NO.6 and SEQ ID NO.7; the reagent capable of quantifying SLC26A2 protein includes an antibody that specifically binds to SLC26A2 protein.

5. The use according to claim 1, characterized in that: The invention also includes the use of an activator of SLC26A2 in preparing a drug for treating tibial chondrodysplasia in broilers.

6. The use according to claim 4, characterized in that: The activator can promote or enhance the expression or activity of SLC26A2 or a substance involved in an upstream or downstream pathway of SLC26A2.

Citation Information

Patent Citations

  • Excrement biomarker for early diagnosis of broiler tibial cartilage dysplasia and application thereof

    CN114088855A

  • Application of SLC26A2 mutation in diagnosis of multiple epiphyseal dysplasia

    CN116970697A

  • Methods of modulating immune function

    US20120219559A1